arrow
R

Robert W. Cross

university of texas system
H指数:43
被引数:6,083

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge

靶向克里米亚-刚果出血热病毒糖蛋白38的人抗体可保护小鼠免受异源病毒挑战

2026-05-150
OA
Discovery and Optimization of First-in-Class Furopyrimidine-Based Inhibitors of Henipaviruses
2026-01-010
PRE
Evaluation of antigen and antibody assays for surveillance of Lassa virus in peri-domestic rodents in southeastern Sierra Leone: a cross-sectional study

评估抗原和抗体检测方法在塞拉利昂东南部近家鼠中拉沙病毒监测中的应用:一项横断面研究

2025-10-230
OAAI
Experimental challenge of African green monkeys with contemporary Hendra virus isolates produces divergent clinical disease

使用当代Hendra病毒分离株对非洲绿猴进行实验性挑战会产生不同的临床疾病。

2025-08-220
OAAI
Lassa fever in African green monkeys: Clinical disease and fatal outcome are associated with systemic viral dissemination and inflammation

拉沙热在非洲绿猴中:临床疾病和致命结局与系统性病毒扩散和炎症相关

2025-08-050
OAAI
Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus

瑞德西韦、mAb114、REGN-EB3 和 ZMapp 对感染了低代次基奎特变种埃博拉病毒的灵长类动物具有部分拯救效果。

2025-04-230
OA
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials

一种基于复制性-vesicular stomatitis virus的拉沙病毒疫苗候选物的临床前开发已进入人体临床试验阶段。

2025-04-010
OAAI
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates

口服奥贝特韦(obeldesivir)可为非人灵长类动物提供针对马尔堡病毒(Marburg virus)的暴露后保护。

2025-01-133
OA
Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates

靶向Nipah病毒融合糖蛋白的交叉反应性mAb的治疗性给药可保护非人类灵长类动物

2024-04-034
PRE
The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms

治疗性单克隆抗体Bamlanivimab不会通过FcR介导的机制增强SARS-CoV-2感染

2023-11-302
OAAI